LamassuBioTech

#BIOPartnering #Biotech #Cancer #Innovation #Oncology

Lamassu BioTech CEO Gabi Hanna MD shared his insights on the challenges and opportunities for companies looking for success in 2026 alongside @rodmrenshaw Senior Biotechnology Analyst @MichaelGKingJr, Bantam Pharmaceutical CEO @MyRxDx, @CreatvMicroTech, Inc. CBO Ron Baker, and Oncode Accelerator Business Development Manager Federica Frati.

Success comes from having a sound understanding of the industry's landscape and what differentiates your company from your competitors. That was the message from biotech leaders during this week's "Catalyzing Cancer Innovation" panel discussion, hosted by @IAmBiotech's BIOPartnering™.

That's why our team works tirelessly each and every day to advance our investigational SA553-therapy, a first-in-class, small-molecule MDM2 inhibitor. This is a significant unmet need globally. We believe that this genetically targeted therapy can bring new hope for patients, especially those dealing with rare cancers who currently have no good treatment options.

On #WorldCancerDay, Lamassu Biotech stands united with the global cancer community as we all work to bring hope and healing to those suffering. Nearly 2 million new cases of cancer are diagnosed annually in the US, with half of all forms of human cancer involving the mutation of the P53 gene.

Advancing access to #genetherapy where patients live matters. Looking forward to being @CCAD on Feb 11–12 to discuss and screen patients with# sicklecell disease and #thalassemia and to help deliver this transformative care closer to home in the UAE. linkedin.com/posts/clevelan…

A great week at @jpmorgan's 44th Annual Healthcare Conference. This will be a pivotal year as our team advances our SA53 MDM2 inhibitor program, a next-generation approach for patients with p53 wild-type solid tumors. This treatment offers hope for those with rare forms of cancer and a targeted alternative where traditional therapies have failed. #CancerResearch #Cancer #Health #Healthcare #JPMorgan #JMP2026 #PrecisionOncology #MDM2 #Biotech #innovation

Click the link to read Dr. Hanna’s full thoughts on leadership, innovation and how we can accelerate hope and healing: lamassubiotech.com/wp-content/upl….

As Dr. Hanna shared, “In biotech, you are always racing against the clock. Patent life starts on day one, and every delay reduces your chances of success. Market windows open and close quickly, and when you miss them, the opportunity disappears, regardless of the quality of your science. Time isn’t a preference to optimize — it is a decisive constraint that shapes everything we do.”

Our CEO, Gabi Hanna, MD, recently sat down with #RBVQuarterly to discuss what makes a successful leader. #Leadership #Biotech #Innovation #Science #Medicine #Oncology #RareDisease #Research

We look forward to connecting with industry leaders and investors to discuss how we can accelerate these life-saving therapies for both human and animal patients. ​#JPM2026 #Biotech #Oncology #OneHealth #ClinicalTrials #AcutePancreatitis #LamassuBiotech #DrugDevelopment #RABI767 #PrecisionOncology

🐾 RABI-767 | Acute Pancreatitis: We are scaling our "One Health" approach to address this significant unmet need. We are particularly excited to advance our LamassuPet animal health program—bringing RABI-767 to canines while simultaneously progressing the human clinical pathway alongside our partners.

Lamassu BioTech's leadership team will be on the ground for the @jpmorgan Healthcare Conference this January to share a year of breakthrough progress and clinical momentum. ​Following highly encouraging data, we are ready to discuss the future of our two lead programs:

12 days of ASHmas Day 2 post : #ASH25 plenaries are always a big deal . This @ASH_hematology I’m excited about 2 studies- 1st one by the amazing @KellyLBolton lab on a huge challenge facing all cancer types - TP53 mutant disease! CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. 2nd study post tomorrow!

5/ Read the full announcement here: lamassubiotech.com/2025/11/03/sa5… #biotech #healthcare #medicine #research #Cancer #cancertreatment

4/ The therapy is being investigated in adult patients with sarcoma and other solid tumors who possess the p53 wild-type gene and who currently have limited therapeutic options.

🧵@LamassuBioTech today announced a significant clinical milestone in its Phase 1/2a trial investigating SA53, a first-in-class, small-molecule MDM2 inhibitor. #biotech #healthcare #medicine #research #Cancer #cancertreatment